LYEL Stock — Lyell Immunopharma Inc

Lyell Immunopharma Inc (LYEL)

Updated October 16, 2026.

LYEL is a Stock. Total return is -97.6% over the past 5.3 years, 192.2 points behind SPY at 94.6%.

Lyell Immunopharma is a clinical-stage cell therapy company developing chimeric antigen receptor (CAR) T-cell treatments for hematologic malignancies and solid tumors, with its lead candidate in pivotal trials for large B-cell lymphoma and a second candidate in early-stage testing for colorectal cancer. The company does not currently distribute to shareholders. This security appeals to investors seeking exposure to early-stage biotechnology and cell therapy development, with an understanding that clinical-stage companies carry significant development and regulatory risks.

LYEL performance versus SPY

Price and return data through 2026-10-16.

Total return is -97.6% over the past 5.3 years, 192.2 points behind SPY at 94.6%. Over the past year its total return — price change plus distributions reinvested — is -52.2%. Its deepest 1-year drawdown was 80.5%.

LYEL key facts

Asset type

Stock

Asset class

Equity

Inception date

06/17/2021

Distribution frequency

None

Last close

$8.12 (as of 2026-10-16)

Market cap

$198,981,745

Average volume

194964.0

Beta

-0.032

Payout ratio

0.0%

EPS

$-12.86

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

LYEL risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 80.5%.

Who may consider LYEL — and who may not

It is a weaker fit for investors who need monthly cash flow (LYEL does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on LYEL

• All tickers starting with L

Tagged: Healthcare.

Frequently asked questions